Preclinical development of MHB042C: A next-generation anti-c-Met ADC conjugating VHH-Fc fusion protein with a novel topoisomerase I inhibitor
1. 文件大小不能超过300M, 允许上传文档或压缩包等
2. 请确保上传文献的真实性、完整性，不得对原文做任何修改
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
B Liu, L Zhu, Y Chen, X Meng, A Li, L Liu, Z Yao…
Cancer …, 2025
aacrjournals.org
Abstract c-MET, a receptor tyrosine kinase encoded by the MET proto-oncogene, is widely expressed in various solid tumors. Antibody-drug conjugates (ADC) targeting c-Met have shown promising clinical activity in patients with high c-MET expression, yet the therapeutic benefit remains limited for those with moderate or low expression levels. Here, we present the development and preclinical characterization of MHB042C, a next-generation anti-c-Met ADC. Unlike conventional monoclonal antibody (mAb), MHB042C utilizes a humanized VHH …
